Argen-X (ARGX.BR) — Quality & forensics
As of 2026-11-02 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 29
- Quality 75
- Growth 86
- Balance sheet 94
- Cash quality 39
- Capital allocation 20
- Momentum 74
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — above the −1.78 threshold the literature flags for earnings-manipulation risk. A screen, not an accusation.
Continue: the ARGX.BR chart & overview
FAQ · from the current data · as of 2026-11-02
Quick answers
What is Argen-X's Closelooknet quality reading?
The composite reads 64/100 across 7 modules, as of 2026-11-02: valuation 29, quality 75, growth 86, balance sheet 94, cash quality 39, capital allocation 20, momentum 74. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Argen-X's Altman Z-Score?
23.99, which sits in the safe zone (above 2.99) as of 2026-11-02. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Argen-X's Piotroski F-Score?
5 of 8, as of 2026-11-02. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Argen-X's Beneish M-Score indicate?
-1.44 — above the −1.78 threshold the literature flags for earnings-manipulation risk, as of 2026-11-02. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ONC BeiGene, Ltd.industry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- REGN Regeneron Pharmaceuticals Incindustry
- RIGL Rigel Pharmaceuticals Incindustry
- KOD Kodiak Sciences Incindustry
- REPL Replimune Group Incindustry
- MRNA Moderna Incindustry
- EXEL Exelixis Incindustry
- ARQT Arcutis Biotherapeutics Incindustry
- VRDN Viridian Therapeutics Incindustry
- XNCR Xencor Incindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- BHVN Biohaven Ltd.industry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- KYMR Kymera Therapeutics Incindustry
- SEPN Septerna, Inc. Common Stockindustry
- ADMA ADMA Biologics Incindustry
- IRON Disc Medicine Inc.industry